Rational formulation strategy from drug discovery profiling to human proof of concept

References

• Amidon GL, Lennernas H, Shah VP, Crison JR. (1995). A theoretical basis for a biopharmaceutics drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413–20
   PubMed Web of Science ®Google Scholar
• Barrett Rabinow E. (2004). Nanosuspensions in drug delivery. Nat Rev Drug Discov 3:785–96
   PubMed Web of Science ®Google Scholar
• Butler JM, Dressman JB. (2010). The developability classification system: application of biopharmaceutics concepts to formulation development. J Pharm Sci 99:4940–54
   PubMed Web of Science ®Google Scholar
• Filippos K, Santipharp P, Yunhui W. (2007). Nanosizing – Oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev 59:631–44
   PubMed Web of Science ®Google Scholar
• Gaud SR, Yeole PG, Yadav AV, Gokhale SB. (2008). Pharmaceutics. 10th Edition. : Nirali Prakashan
   Google Scholar
• Guidance for Industry Extended Release Oral Dosage Forms. (1997). Development, evaluation, and application of in vitro/in vivo correlations. : Food and Drug Administration
   Google Scholar
• Guidance for Industry, ANDAs. (2007). Pharmaceutical solid polymorphism. : Food and Drug Administration
   Google Scholar
• Ismail K, John L. (2004). Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711–16
   PubMed Web of Science ®Google Scholar
• Jochen M, Walter K, Gerrit H. (2007). An integrated early formulation strategy – From hit evaluation to preclinical candidate profiling. Eur J Pharm Biopharm 66:1–10
   PubMed Web of Science ®Google Scholar
• Johan W, Luc Q. (2011). Pharmaceutical Salts and Co-crystals. : Royal Society of Chemistry Publishing
   Google Scholar
• Kathryn W, Natalie K, Samir M. (2008). Safe and effective permeation enhancers for oral drug delivery. Pharm Res 25:1782–8
   PubMed Web of Science ®Google Scholar
• Klein C, Y-Chiu L, Awni W, et al. (2008). A pivotal biostudy comparing ritonavir 100 mg film-coated tablet to a ritonavir 100 mg soft gelatin capsule in healthy adult subjects. Oral Abstract Session: AIDS 2008 – XVII International AIDS Conference: Abstract no. THAB0405, Mexico City, Mexico
   Google Scholar
• Leslie Benet Z, Chi-Yuan Wu, Joseph MC. (2006). Predicting drug absorption and the effects of food on oral bioavailability, Bulletin technique Gattefosse Number 99, Académie des Alpilles
   Google Scholar
• Lipinski CA. (2000). Drug-like properties and causes of poor solubility and poor permeability. J PharmacolToxicol Methods 44:235–49
   Google Scholar
• Madhusudan H, Loksidh DG, Gregory EA, et al. (2003). Reducing the time to develop and manufacture formulations for first oral dose in humans. Pharm Technol 27:68
   Google Scholar
• Marc L, Sabine K, Jennifer Dressman B. (2004). Classification of orally administered drugs on the world health organization model list of essential medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm 58:265–78
   PubMed Web of Science ®Google Scholar
• Martin K. (2008). Drug absorption modeling as a tool to define the strategy in clinical formulation development. AAPS J 10:473–9
   PubMed Web of Science ®Google Scholar
• Michael P, John Higgins D, Elizabeth K, Allen Templeton C. (2010). Strategies at the interface of drug discovery and development: early optimization of the solid state phase and preclinical toxicology formulation for potential drug candidates. J Med Chem 53:5897–905
   PubMed Web of Science ®Google Scholar
• Mohamad Ayad H, Beatrice B, Jacques Q, et al. (2012). Amorphous solid dispersion successfully improved oral exposure of ADX71943 in support of toxicology studies. Drug Dev Ind Pharm 39:1–6
   PubMed Web of Science ®Google Scholar
• Mohanraj P, Jasmina K. (2011). Solid dispersion of prednisolone: solid state characterization and improvement of dissolution profile. Drug Dev Ind Pharm 37:373–86
   PubMed Web of Science ®Google Scholar
• Munir Hussain A.(2011). Oral drug delivery: solubility & dissolution rate, oral absorption, and strategies to enable a successful and speedy transition from FIH to drug product, oral presentation AAPS annual meeting, Washington DC
   Google Scholar
• Ping L, Luwei Z. (2007). Developing early formulation: practice and perspective, Int. J. Pharm 341:1–9
   Google Scholar
• Pradeep P, Vandana P, Anant P. (2007). Formulation of a self-emulsifying system for oral delivery of simvastatin: in vitro and in vivo evaluation. Acta Pharm 57:111–22
   PubMedGoogle Scholar
• Ran Y, Jain N, Yalkowsky SH. (2011). Prediction of aqueous solubility of organic compounds by the general solubility equation (GSE). Chem J Inf Comput Sci 41:1208–17
   Web of Science ®Google Scholar
• Rinaki E, Valsami G, Macheras P. (2003). quantitative biopharmaceutics classification system: the central role of dose/solubility ratio. Pharma Res 20:1917–25
   Web of Science ®Google Scholar
• Sashadri N. (2006). Preclinical formulations for discovery and toxicology: physicochemical challenges. Expert Opin Drug Metab Toxicol 2:715–31
   PubMed Web of Science ®Google Scholar
• Sherry MK. (2008). Use of the biopharmaceutical classification system in early drug development. AAPS J 10:208–12
   PubMed Web of Science ®Google Scholar
• Sherry MK. (2006). An oral formulation decision tree based on biopharmaceutical classification system for first-in-human clinical trial. Bulletin technique Gattefosse Number 98, Académie des Alpilles
   Google Scholar
• Sherry MK, Wendy D. (2010). A biopharmaceutical classification-based Right-First-Time formulation approach to reduce human pharmacokinetic variability and project cycle time from First-In-Human to clinical Proof-Of-Concept. Pharm Dev Technol 17:285–302
   PubMed Web of Science ®Google Scholar
• Shui-Mei K, Andrew Humberstone J, Christopher J, et al. (1998). Formulation design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrine. Int J Pharm 167:155–64
   Web of Science ®Google Scholar
• Stephen Buckley T, Sarah Fischer M, Gert F, Martin B. (2012). In vitro models to evaluate the permeability of poorly soluble drug entities: challenges and perspectives. Eur J Pharm Biopharm 45:235–50
   Web of Science ®Google Scholar
• Uwe M, Christian P, Thomas B, et al. (2011). Volume to dissolve applied dose (VDAD) and apparent dissolution rate (ADR): tools to predict in vivo bioavailability from orally applied drug suspensions. Eur J Pharm Biopharm 78:522–30
   PubMed Web of Science ®Google Scholar
• Uwe M. (2010). Volume to dissolve applied dose (VDAD) and apparent dissolution rate (ADR) – tools to predict in vivo bioavailability from orally applied drug suspensions. Phys Chem Forum 9, Barcelona, Spain
   Google Scholar